SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2002-12-3637. This Article Full Text (PDF) All Versions of this Article: 2002-12-3637v1 102/4/1224    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cwynarski, K. Articles by Apperley, J F Search for Related Content PubMed PubMed Citation Articles by Cwynarski, K. Articles by Apperley, J F Related Collections Related Article in Blood Online Social Bookmarking                   What's this? Submitted December 3, 2002 Accepted April 9, 2003 Stem cell transplantation for chronic myeloid leukemia in children Kate Cwynarski, Irene A G Roberts*, Simona Iacobelli, Anja van Biezen, Ronald Brand, Agnes Devergie, J M Vossen, M Aljurf, W Arcese, F Locatelli, G Dini, D Niethammer, D Niederwieser, and J F Apperley Department of Haematology, Imperial College Faculty of Medicine, Hammersmith Hospital, London, United Kingdom; Paediatric and Chronic Leukaemia Working Parties of the EBMT * Corresponding author; email: irene.roberts{at}ic.ac.uk. Hematopoietic stem cell transplantation (SCT) is the only proven cure for chronic myeloid leukemia (CML), a rare disease in childhood. We report outcome of 314 children with Ph-positive CML undergoing SCT from HLA-matched siblings (n=182) or volunteer-unrelated donors (VUD; n=132). Three-year overall survival (OS) and leukemia-free survival (LFS) were 66% and 55% (n=314). For 156 children in first chronic phase (CP1) transplanted from HLA-identical siblings OS and LFS were 75% and 63%. For 97 children transplanted in CP1 using VUD SCT 3-year OS and LFS were 65% and 56% reflecting higher transplant-related mortality (TRM) after VUD SCT (35% vs 20%; multivariate HR: 1.9: 95% CI: 1.0-3.5; p=0.05). In a multivariate model for OS and LFS outcome was superior in CP1 versus advanced phase (AP:CP1 OS HR 2.0 [95% CI: 1.3-3]; p=0.001 and LFS HR 1.8 [95% CI: 1.2-2.6]; p=0.003). For relapse, donor source (VUD:sibling HR 0.38 (95% CI: 0.19-0.76; p=0.006) and disease stage were significant (AP: CP1 HR 2.4 (95% CI: 1.36-4.3; p=0.003). This is the first large series to show that SCT confers long-term LFS in the majority of children with CML and helps assess alternative therapy, including tyrosine kinase inhibitors, in children. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Build it and they will come (or will they?) James T. Casper Blood 2003 102: 1150. [Full Text] [PDF] This article has been cited by other articles: T. Littlewood, R. Malladi, and A. Peniket No more transplantation in CML? Blood, December 15, 2007; 110(13): 4618 - 4618. [Full Text] [PDF] R. Hehlmann, A. Gratwohl, M. Pfirrmann, J. Hasford, A. Hochhaus, D. K. Hossfeld, and H. Heimpel Response: Drug treatment and allografting as first-line therapy in young patients with CML Blood, December 15, 2007; 110(13): 4618 - 4619. [Full Text] [PDF] M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF] B. N. Savani, K. Rezvani, S. Mielke, A. Montero, R. Kurlander, C. S. Carter, S. Leitman, E. J. Read, R. Childs, and A. J. Barrett Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia Blood, February 15, 2006; 107(4): 1688 - 1695. [Abstract] [Full Text] [PDF] M. A. Champagne, R. Capdeville, M. Krailo, W. Qu, B. Peng, M. Rosamilia, M. Therrien, U. Zoellner, S. M. Blaney, and M. Bernstein Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study Blood, November 1, 2004; 104(9): 2655 - 2660. [Abstract] [Full Text] [PDF] R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF] M. Boeckh and W. G. Nichols The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy Blood, March 15, 2004; 103(6): 2003 - 2008. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020